Page 1

Verici Dx plc ( " Verici Dx " or the " Company " ) Half - year report Verici Dx plc ( AIM : VRCI ) , a developer of advanced clinical diagnostics for organ transplant , announces its unaudited interim results for the six months ended 30 June 2026 ( " H1 2026 " ) . Financial highlights • Revenues of $ 1.8m ( H1 2025 : $ 1.9m ; FY 2025 : $ 3.7m ) Includes Tutivia testing revenues up 53 % . 2025 includes $ 0.75m of licensing revenues from Thermo Fischer Tutivia testing Licensing revenues H1 2026 H1 2025 FY2025 US $ m US $ m US $ m 1.77 1.16 2.86 0.75 0.81 1.77 1.91 3.66 • Adjusted EBITDA¹ loss of $ 3.5m ( H1 2025 : loss of $ 2.8m ; FY 2025 : loss of $ 6.2m ) • $ 2.4m cash balance as at 30 June 2026 ( 31 December 2025 : $ 3.3m ) • Net cash outflow from operating activities of $ 3.8m ( H1 2025 : $ 3.5m outflow ; FY 2025 : $ 8.3m outflow ) • Equity fundraise completed in June 2026 raising gross proceeds of £ 2.6m ( $ 3.4m ) • • Today the Company has announced separately that it is proposing a further equity fundraise to support the Company's growth plans Operational highlights • • Tutivia testing volumes continue to increase quarter - on - quarter at a steady growth rate with Q3 2026 on track for a 53 % increase in orders year on year 32 transplant centres onboarded and ordering tests in H1 2026 , with a further three onboarded since 30 June The 35 centres currently using Tutivia ™ now represent 23 % of annual kidney transplants in the US ( based upon UNOS.org data ) • Average reimbursement rate of $ 2,300 per test being achieved • • • Appointment of Keith Gilliard as Senior Sales Director Agreement with Blue Cross and Blue Shield ( ' BCBS ' ) of Illinois for Tutivia ™ , with contracted pricing across multiple lines of business , giving in - network status for BCBS covered patients and providing access to open contract processes with other BCBS entities Protega ™ granted an additional CPT® Proprietary Laboratory Analyses ( ' PLA ' ) code by the American Medical Association ( ' AMA ' ) which is fundamental for commercial reimbursement 1 Earnings before income tax , depreciation and amortisation , adjusted to exclude share - based payments Commenting on Outlook , Sara Barrington , Chief Executive Officer of Verici Dx , said : " H1 2026 has been a positive and progressive period for Verici . We continue to increase the number of centres ordering Tutivia and pleasingly three of the recent centres have already moved to high recurring ordering . Our current team of four business development directors , led by our recently appointed Senior Sales Director , Keith Gilliard , have delivered excellent revenue growth in Tutivia in the period and I am confident that that momentum will continue into H2 2026 and beyond . " A copy of the Company's interim results report will shortly be made available on the Company's website . Enquiries : Verici Dx plc Sara Barrington , CEO Julian Baines , Chairman Singer Capital Markets ( Nominated Adviser & Joint Broker ) Alex Bond / Russell Cook Oberon Capital ( Joint Broker ) Mike Seabrook / Adam Pollock Walbrook PR ( Media & Investor Relations ) Alice Woodings / Rachel Broad www.vericidx.com Via Walbrook PR Tel : +44 ( 0 ) 20 7496 3000 Tel : +44 ( 0 ) 20 3179 0500 Tel : +44 ( 0 ) 20 7933 8780 or vericidx@walbrookpr.com Mob : +44 ( 0 ) 7407 804 654 / +44 ( 0 ) 7747 515 393 WHERE COMPLEXITY MEETS CLARITY About Verici Dx plc www.vericidx.com